How can you tell if a drug has nonlinear kinetics?

By examining whether exposure (such as area under the curve) increases in proportion to dose; a disproportionate rise or fall in exposure, or a change in half-life or clearance with dose, indicates a saturable, nonlinear process.

What is the most common cause of nonlinear pharmacokinetics?

Saturation of a capacity-limited elimination pathway, typically a metabolising enzyme, which makes clearance fall and exposure rise disproportionately as concentration approaches the enzyme's saturation range; saturable transport and protein binding can also contribute.

Linear Versus Nonlinear Kinetics

Pharmacokinetics is called linear when drug exposure scales in proportion to the dose, so that doubling the dose doubles the concentration and the area under the curve while parameters such as clearance and half-life stay constant. It is called nonlinear when one or more disposition processes saturate, so that exposure changes disproportionately with dose and the parameters themselves vary with concentration.

Definition

Linear kinetics describes drug disposition in which clearance and volume of distribution are independent of dose and concentration, so that exposure is proportional to dose; nonlinear kinetics describes disposition in which a saturable process makes one or more parameters concentration-dependent, so that exposure is not proportional to dose.

Scope

This topic explains the distinction between dose-proportional (linear) and saturable (nonlinear) kinetics, the processes that cause nonlinearity, and how nonlinear behaviour is recognised and described, including capacity-limited (Michaelis-Menten) elimination. It is a conceptual and quantitative entry for reference and education, and does not provide dosing guidance.

Core questions

When does drug exposure scale proportionally with dose, and when does it not?
Which physiological processes can saturate and cause nonlinear kinetics?
How is nonlinearity detected from dose-exposure data?
How does capacity-limited (Michaelis-Menten) elimination differ from first-order elimination?

Key concepts

Dose proportionality (superposition principle)
First-order versus zero-order processes
Saturable metabolism and transport
Saturable protein binding
Capacity-limited (Michaelis-Menten) elimination
Concentration-dependent clearance and half-life

Key theories

Capacity-limited (Michaelis-Menten) elimination: When an enzyme or transporter mediating elimination approaches saturation, the elimination rate follows Michaelis-Menten kinetics rather than remaining first-order, so that clearance falls and half-life lengthens as concentration rises, producing disproportionate increases in exposure with dose.

Mechanisms

Most drug-handling processes — passive diffusion, glomerular filtration, many metabolic and transport pathways at usual concentrations — operate far below their capacity and behave as first-order processes, meaning the rate is proportional to concentration. When this holds throughout, kinetics are linear: parameters are constant and concentration-time profiles for different doses are scalable copies of one another (the superposition principle). Nonlinearity arises when a capacity-limited process becomes saturated. Saturable metabolism is the classic example: as concentration rises toward the enzyme's Michaelis constant, the elimination rate approaches a maximum, clearance decreases, half-life increases, and exposure rises faster than dose. Saturable transport, saturable protein binding, and saturable absorption can produce nonlinearity in either direction. Because the parameters then depend on concentration, the simple proportional scaling of linear kinetics no longer applies, and the system is described with concentration-dependent expressions such as the Michaelis-Menten model of elimination.

Clinical relevance

Whether a drug behaves linearly or nonlinearly determines how exposure responds to changes in dose, which is important when interpreting pharmacokinetic studies and concentration data. Nonlinear drugs show disproportionate changes in exposure that the literature treats as a distinct and clinically significant behaviour. This entry describes the underlying kinetics for reference; it does not provide dosing recommendations or individualised advice.

Evidence & guidelines

The mechanisms and clinical implications of nonlinear pharmacokinetics are reviewed by Ludden and codified in standard texts (Gibaldi and Perrier; Rowland and Tozer), with historical context from Wagner. These are reference and educational sources rather than clinical practice guidelines.

History

First-order, dose-proportional models dominated early pharmacokinetics, but cases of saturable disposition were recognised as the discipline matured, drawing the Michaelis-Menten formalism from enzyme kinetics into the description of drug elimination. Wagner's history records this broadening of scope, and reviews such as Ludden's consolidated the clinical implications of nonlinear behaviour.

Key figures

Thomas M. Ludden
John G. Wagner
Milo Gibaldi
Malcolm Rowland
Thomas N. Tozer

Seminal works

ludden-1991
gibaldi-perrier-1982

Frequently asked questions

How can you tell if a drug has nonlinear kinetics?: By examining whether exposure (such as area under the curve) increases in proportion to dose; a disproportionate rise or fall in exposure, or a change in half-life or clearance with dose, indicates a saturable, nonlinear process.
What is the most common cause of nonlinear pharmacokinetics?: Saturation of a capacity-limited elimination pathway, typically a metabolising enzyme, which makes clearance fall and exposure rise disproportionately as concentration approaches the enzyme's saturation range; saturable transport and protein binding can also contribute.